

Jean-Philippe GuÃ©gan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4307537/publications.pdf>

Version: 2024-02-01

13
papers

498
citations

933447

10
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

642
citing authors

#	ARTICLE	IF	CITATIONS
1	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. <i>Nature Cancer</i> , 2021, 2, 794-802.	13.2	173
2	Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial. <i>Clinical Cancer Research</i> , 2021, 27, 2139-2147.	7.0	77
3	Nonapoptotic functions of Fas/CD95 in the immune response. <i>FEBS Journal</i> , 2018, 285, 809-827.	4.7	56
4	The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control. <i>International Journal of Hepatology</i> , 2012, 2012, 1-13.	1.1	43
5	MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells. <i>Carcinogenesis</i> , 2013, 34, 38-47.	2.8	41
6	Disrupting the CD95-PLC γ 3 interaction prevents Th17-driven inflammation. <i>Nature Chemical Biology</i> , 2018, 14, 1079-1089.	8.0	23
7	Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis. <i>Science Translational Medicine</i> , 2021, 13, eabi4994.	12.4	22
8	MEK1/2 Overactivation Can Promote Growth Arrest by Mediating ERK1/2-Dependent Phosphorylation of p70S6K. <i>Journal of Cellular Physiology</i> , 2014, 229, 903-915.	4.1	20
9	The complexity of ERK1 and ERK2 MAPKs in multiple hepatocyte fate responses. <i>Journal of Cellular Physiology</i> , 2012, 227, 59-69.	4.1	17
10	CD95/Fas suppresses NF- κ B activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism. <i>iScience</i> , 2021, 24, 103538.	4.1	16
11	Signaling by the tyrosine kinase Yes promotes liver cancer development. <i>Science Signaling</i> , 2022, 15, eabj4743.	3.6	7
12	Synthesis of peptidomimetics and chemo-biological tools for CD95/PLC γ 3 interaction analysis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2094-2099.	2.2	1
13	Probing the side chain tolerance for inhibitors of the CD95/PLC γ 3 interaction. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126669.	2.2	1